Headlines about Versartis (NASDAQ:VSAR) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Versartis earned a news impact score of 0.05 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.959927233567 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern’s rankings:
- Analysts’ Recommendation in Spotlight: Versartis Inc (NASDAQ: VSAR) – Alpha Beta Stock (alphabetastock.com)
- Today’s Brokerage Rating: Versartis, Inc., (NASDAQ: VSAR), RH, (NYSE: RH), Dover Corporation, (NYSE: DOV … – Stocks In The News (press release) (tradingnewsnow.com)
- Technical Review on Versartis, Inc. (VSAR) | Wallstreet Morning – Wall Street Morning (wallstreetmorning.com)
- Versartis, Inc. (VSAR) noted a price change of -5.41% and Surgery Partners, Inc. (SGRY) closes with a move of -0.63% – Stocks Gallery (stocksgallery.com)
A number of research analysts have commented on VSAR shares. ValuEngine downgraded Versartis from a “sell” rating to a “strong sell” rating in a research note on Friday, September 22nd. Cantor Fitzgerald set a $34.00 target price on Versartis and gave the company a “buy” rating in a research note on Thursday, July 27th. Zacks Investment Research upgraded Versartis from a “sell” rating to a “hold” rating in a research note on Wednesday, August 30th. SunTrust Banks, Inc. downgraded Versartis from a “buy” rating to a “hold” rating and lowered their target price for the company from $25.00 to $4.00 in a research note on Friday, September 22nd. Finally, Canaccord Genuity restated a “buy” rating and issued a $9.00 target price (down previously from $28.00) on shares of Versartis in a research note on Friday, September 22nd. One research analyst has rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $7.22.
Versartis (VSAR) traded up $0.13 on Tuesday, hitting $1.90. The stock had a trading volume of 1,327,200 shares, compared to its average volume of 806,823. Versartis has a 52 week low of $1.60 and a 52 week high of $24.00. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.11.
Versartis (NASDAQ:VSAR) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.78). During the same period in the prior year, the company posted ($0.92) earnings per share. equities research analysts forecast that Versartis will post -4.14 earnings per share for the current year.
In other news, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of the company’s stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $3.29, for a total transaction of $7,007,700.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders have sold 2,132,769 shares of company stock valued at $7,014,761. 10.90% of the stock is currently owned by corporate insiders.
Versartis Company Profile
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.